Skip to main content
Erschienen in: European Archives of Psychiatry and Clinical Neuroscience 1/2010

01.02.2010 | Special Issue

Meta-analyses: a method to maximise the evidence from clinical studies?

verfasst von: Wolfgang Maier, Hans-Jürgen Möller

Erschienen in: European Archives of Psychiatry and Clinical Neuroscience | Ausgabe 1/2010

Einloggen, um Zugang zu erhalten

Abstract

Evidence-based medicine (EBM) is becoming the guiding principle for clinical treatment decisions. But evidence remains a loosely defined term. Multiple criteria for evidence criteria have been proposed. Most influential evidence criteria give priority to meta-analyses because they promise an objective procedure to combine the outcomes of all informative, putatively conflicting studies on the same issue in an overall score. However, we claim that meta-analyses are of limited informative value for the following six reasons: (1) meta-analyses are often “overpowered” with clinically irrelevant results that might emerge as highly significant; (2) there is serious concern of publication biases with “negative” studies not being published; (3) meta-analyses consider the variation in the results of the empirical studies included to be random noise, however, the variability of results across studies can be informative; (4) the result of a meta-analysis depends on the strategy used to identify the included empirical studies; (5) the quality of conclusions from meta-analyses depends on the statistical tests used to combine the results of the separate studies; (6) the qualitative conclusions drawn from the meta-analytical combination of individual studies may depend on specific design aspects of the individual studies. Thus, meta-analyses are primarily a method to generate hypotheses through an a posteriori analysis of treatment effects.
Literatur
1.
Zurück zum Zitat Altman DG, Schulz KF, Moher D, Egger M, Davidoff F, Elbourne D, Gotzsche PC, Lang T (2001) The revised CONSORT statement for reporting randomized trials: explanation and elaboration. Ann Intern Med 134:663–694PubMed Altman DG, Schulz KF, Moher D, Egger M, Davidoff F, Elbourne D, Gotzsche PC, Lang T (2001) The revised CONSORT statement for reporting randomized trials: explanation and elaboration. Ann Intern Med 134:663–694PubMed
2.
Zurück zum Zitat Anderson IM (1998) SSRIS versus tricyclic antidepressants in depressed inpatients: a meta-analysis of efficacy and tolerability. Depress Anxiety 7(Suppl 1):11–17CrossRefPubMed Anderson IM (1998) SSRIS versus tricyclic antidepressants in depressed inpatients: a meta-analysis of efficacy and tolerability. Depress Anxiety 7(Suppl 1):11–17CrossRefPubMed
3.
Zurück zum Zitat Anderson IM (2000) Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. J Affect Disord 58:19–36CrossRefPubMed Anderson IM (2000) Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. J Affect Disord 58:19–36CrossRefPubMed
4.
Zurück zum Zitat Bandelow B, Zohar J, Hollander E, Kasper S, Möller HJ et al (2008) World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive–compulsive and post-traumatic stress disorders—first revision. World J Biol Psychiatry 9:248–312CrossRefPubMed Bandelow B, Zohar J, Hollander E, Kasper S, Möller HJ et al (2008) World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive–compulsive and post-traumatic stress disorders—first revision. World J Biol Psychiatry 9:248–312CrossRefPubMed
5.
Zurück zum Zitat Bandelow B, Zohar J, Kasper S, Möller HJ (2008) How to grade categories of evidence. World J Biol Psychiatry 9:242–247CrossRefPubMed Bandelow B, Zohar J, Kasper S, Möller HJ (2008) How to grade categories of evidence. World J Biol Psychiatry 9:242–247CrossRefPubMed
6.
Zurück zum Zitat Bauer M, Whybrow P, Angst J, Versiani M, Möller H-J (2004) Biologische Behandlung unipolarer depressiver Störungen. Behandlungsleitlinien der World Federation of Societies of Biological Psychiatry (WFSBP), Stuttgart, Wissenschaftliche Verlagsgesellschaft Bauer M, Whybrow P, Angst J, Versiani M, Möller H-J (2004) Biologische Behandlung unipolarer depressiver Störungen. Behandlungsleitlinien der World Federation of Societies of Biological Psychiatry (WFSBP), Stuttgart, Wissenschaftliche Verlagsgesellschaft
7.
Zurück zum Zitat Broich K (2009) Committee for Medicinal Products for Human Use (CHMP) assessment on efficacy of antidepressants. Eur Neuropsychopharmacol 19:305–308CrossRefPubMed Broich K (2009) Committee for Medicinal Products for Human Use (CHMP) assessment on efficacy of antidepressants. Eur Neuropsychopharmacol 19:305–308CrossRefPubMed
8.
Zurück zum Zitat Chan AW (2008) Bias, spin, and misreporting: time for full access to trial protocols and results. PLoS Med 5:e230CrossRefPubMed Chan AW (2008) Bias, spin, and misreporting: time for full access to trial protocols and results. PLoS Med 5:e230CrossRefPubMed
9.
Zurück zum Zitat Cipriani A, Furukawa TA, Salanti G, Geddes JR, Higgins JPT, Churchill R, Watanabe N, Nakagawa A, Omori IM, McGuire H, Tansella M, Barbui C (2009) Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet 273:746–758 Cipriani A, Furukawa TA, Salanti G, Geddes JR, Higgins JPT, Churchill R, Watanabe N, Nakagawa A, Omori IM, McGuire H, Tansella M, Barbui C (2009) Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet 273:746–758
10.
Zurück zum Zitat Feinstein AR (1995) Meta-analysis: statistical alchemy for the 21st century. J Clin Epidemiol 48:71–79 CrossRefPubMed Feinstein AR (1995) Meta-analysis: statistical alchemy for the 21st century. J Clin Epidemiol 48:71–79 CrossRefPubMed
11.
Zurück zum Zitat Fergusson D, Doucette S, Glass KC, Shapiro S, Healy D, Hebert P, Hutton B (2005) Association between suicide attempts and selective serotonin reuptake inhibitors: systematic review of randomised controlled trials. BMJ 330:396. doi:10.1136/bmj.330.7488.396 CrossRefPubMed Fergusson D, Doucette S, Glass KC, Shapiro S, Healy D, Hebert P, Hutton B (2005) Association between suicide attempts and selective serotonin reuptake inhibitors: systematic review of randomised controlled trials. BMJ 330:396. doi:10.​1136/​bmj.​330.​7488.​396 CrossRefPubMed
12.
Zurück zum Zitat Geddes J, Freemantle N, Harrison P, Bebbington P (2000) Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 321:1371–1376CrossRefPubMed Geddes J, Freemantle N, Harrison P, Bebbington P (2000) Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 321:1371–1376CrossRefPubMed
13.
Zurück zum Zitat Geddes J, Harrison P, Freemantle N (2003) New generation versus conventional antipsychotics. Lancet 362:404–405CrossRefPubMed Geddes J, Harrison P, Freemantle N (2003) New generation versus conventional antipsychotics. Lancet 362:404–405CrossRefPubMed
14.
Zurück zum Zitat Gibbons RD, Hur K, Bhaumik DK, Mann JJ (2005) The relationship between antidepressant medication use and rate of suicide. Arch Gen Psychiatry 62:165–172CrossRefPubMed Gibbons RD, Hur K, Bhaumik DK, Mann JJ (2005) The relationship between antidepressant medication use and rate of suicide. Arch Gen Psychiatry 62:165–172CrossRefPubMed
15.
Zurück zum Zitat Gunnell D, Saperia J, Ashby D (2005) Selective serotonin reuptake inhibitors (SSRIs) and suicide in adults: meta-analysis of drug company data from placebo controlled, randomised controlled trials submitted to the MHRA’s safety review. BMJ 330:385. doi:10.1136/bmj.330.7488.385 CrossRefPubMed Gunnell D, Saperia J, Ashby D (2005) Selective serotonin reuptake inhibitors (SSRIs) and suicide in adults: meta-analysis of drug company data from placebo controlled, randomised controlled trials submitted to the MHRA’s safety review. BMJ 330:385. doi:10.​1136/​bmj.​330.​7488.​385 CrossRefPubMed
16.
Zurück zum Zitat Hayashino Y, Noguchi Y, Fukui T (2005) Systematic evaluation and comparison of statistical tests for publication bias. J Epidemiol 15:235–243CrossRefPubMed Hayashino Y, Noguchi Y, Fukui T (2005) Systematic evaluation and comparison of statistical tests for publication bias. J Epidemiol 15:235–243CrossRefPubMed
17.
Zurück zum Zitat Ioannidis JP, Trikalinos TA (2007) The appropriateness of asymmetry tests for publication bias in meta-analyses: a large survey. CMAJ 176:1091–1096PubMed Ioannidis JP, Trikalinos TA (2007) The appropriateness of asymmetry tests for publication bias in meta-analyses: a large survey. CMAJ 176:1091–1096PubMed
18.
Zurück zum Zitat Jüni P, Altman DG, Egger M (2001) Systematic reviews in health care: assessing the quality of controlled clinical trials. BMJ 323:42–46CrossRefPubMed Jüni P, Altman DG, Egger M (2001) Systematic reviews in health care: assessing the quality of controlled clinical trials. BMJ 323:42–46CrossRefPubMed
19.
Zurück zum Zitat Khan A, Kolts RL, Thase ME, Krishnan KR, Brown W (2004) Research design features and patient characteristics associated with the outcome of antidepressant clinical trials. Am J Psychiatry 161:2045–2049CrossRefPubMed Khan A, Kolts RL, Thase ME, Krishnan KR, Brown W (2004) Research design features and patient characteristics associated with the outcome of antidepressant clinical trials. Am J Psychiatry 161:2045–2049CrossRefPubMed
20.
Zurück zum Zitat Khan A, Schwartz K (2005) Study designs and outcomes in antidepressant clinical trials. Essent Psychopharmacol 6:221–226PubMed Khan A, Schwartz K (2005) Study designs and outcomes in antidepressant clinical trials. Essent Psychopharmacol 6:221–226PubMed
21.
Zurück zum Zitat Kirsch I, Deacon BJ, Huedo-Medina TB, Scoboria A, Moore TJ, Johnson BT (2008) Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Med 5:e45CrossRefPubMed Kirsch I, Deacon BJ, Huedo-Medina TB, Scoboria A, Moore TJ, Johnson BT (2008) Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Med 5:e45CrossRefPubMed
22.
Zurück zum Zitat Leucht S, Barnes TR, Kissling W, Engel RR, Correll C, Kane JM (2003) Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials. Am J Psychiatry 160:1209–1222CrossRefPubMed Leucht S, Barnes TR, Kissling W, Engel RR, Correll C, Kane JM (2003) Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials. Am J Psychiatry 160:1209–1222CrossRefPubMed
23.
Zurück zum Zitat Leucht S, Wahlbeck K, Hamann J, Kissling W (2003) New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet 361:1581–1589CrossRefPubMed Leucht S, Wahlbeck K, Hamann J, Kissling W (2003) New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet 361:1581–1589CrossRefPubMed
24.
Zurück zum Zitat Melander H, Ahlqvist-Rastad J, Meijer G, Beermann B (2003) Evidence b(i)ased medicine—selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications. BMJ 326:1171–1173CrossRefPubMed Melander H, Ahlqvist-Rastad J, Meijer G, Beermann B (2003) Evidence b(i)ased medicine—selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications. BMJ 326:1171–1173CrossRefPubMed
25.
Zurück zum Zitat Möller H-J (2008) Isn’t the efficacy of antidepressants clinically relevant? A critical comment on the results of the metaanalysis by Kirsch et al. 2008. Eur Arch Psychiatry Clin Neurosci 258:451–455CrossRefPubMed Möller H-J (2008) Isn’t the efficacy of antidepressants clinically relevant? A critical comment on the results of the metaanalysis by Kirsch et al. 2008. Eur Arch Psychiatry Clin Neurosci 258:451–455CrossRefPubMed
26.
Zurück zum Zitat Möller H-J, Maier W (2009) Evidence-based medicine in psychopharmacotherapy: possibilities, problems and limitations. Eur Arch Psychiatry Clin Neurosci [Epub ahead of print] Möller H-J, Maier W (2009) Evidence-based medicine in psychopharmacotherapy: possibilities, problems and limitations. Eur Arch Psychiatry Clin Neurosci [Epub ahead of print]
27.
29.
Zurück zum Zitat Rising K, Bacchetti P, Bero L (2008) Reporting bias in drug trials submitted to the Food and Drug Administration: review of publication and presentation. PLoS Med 5:e217CrossRefPubMed Rising K, Bacchetti P, Bero L (2008) Reporting bias in drug trials submitted to the Food and Drug Administration: review of publication and presentation. PLoS Med 5:e217CrossRefPubMed
30.
Zurück zum Zitat Stahl SM (2002) Antipsychotic polypharmacy: evidence based or eminence based? Acta Psychiatr Scand 106:321–322CrossRefPubMed Stahl SM (2002) Antipsychotic polypharmacy: evidence based or eminence based? Acta Psychiatr Scand 106:321–322CrossRefPubMed
31.
Zurück zum Zitat Sterne JA, Gavaghan D, Egger M (2000) Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature. J Clin Epidemiol 53:1119–1129CrossRefPubMed Sterne JA, Gavaghan D, Egger M (2000) Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature. J Clin Epidemiol 53:1119–1129CrossRefPubMed
32.
Zurück zum Zitat Turner EH, Matthews AM, Linardatos E, Tell RA, Rosenthal R (2008) Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med 358:252–260CrossRefPubMed Turner EH, Matthews AM, Linardatos E, Tell RA, Rosenthal R (2008) Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med 358:252–260CrossRefPubMed
33.
Zurück zum Zitat Walsh BT, Seidman SN, Sysko R, Gould M (2002) Placebo response in studies of major depression: variable, substantial, and growing. JAMA 287:1840–1847CrossRefPubMed Walsh BT, Seidman SN, Sysko R, Gould M (2002) Placebo response in studies of major depression: variable, substantial, and growing. JAMA 287:1840–1847CrossRefPubMed
34.
Zurück zum Zitat Williams DD, Garner J (2002) The case against “the evidence”: a different perspective on evidence-based medicine. Br J Psychiatry 180:8–12CrossRefPubMed Williams DD, Garner J (2002) The case against “the evidence”: a different perspective on evidence-based medicine. Br J Psychiatry 180:8–12CrossRefPubMed
35.
Zurück zum Zitat Winblad B, Jones RW, Wirth Y, Stoffler A, Mobius HJ (2007) Memantine in moderate to severe Alzheimer’s disease: a meta-analysis of randomised clinical trials. Dement Geriatr Cogn Disord 24:20–27CrossRefPubMed Winblad B, Jones RW, Wirth Y, Stoffler A, Mobius HJ (2007) Memantine in moderate to severe Alzheimer’s disease: a meta-analysis of randomised clinical trials. Dement Geriatr Cogn Disord 24:20–27CrossRefPubMed
Metadaten
Titel
Meta-analyses: a method to maximise the evidence from clinical studies?
verfasst von
Wolfgang Maier
Hans-Jürgen Möller
Publikationsdatum
01.02.2010
Verlag
D. Steinkopff-Verlag
Erschienen in
European Archives of Psychiatry and Clinical Neuroscience / Ausgabe 1/2010
Print ISSN: 0940-1334
Elektronische ISSN: 1433-8491
DOI
https://doi.org/10.1007/s00406-009-0068-3

Weitere Artikel der Ausgabe 1/2010

European Archives of Psychiatry and Clinical Neuroscience 1/2010 Zur Ausgabe

ADHS-Medikation erhöht das kardiovaskuläre Risiko

16.05.2024 Herzinsuffizienz Nachrichten

Erwachsene, die Medikamente gegen das Aufmerksamkeitsdefizit-Hyperaktivitätssyndrom einnehmen, laufen offenbar erhöhte Gefahr, an Herzschwäche zu erkranken oder einen Schlaganfall zu erleiden. Es scheint eine Dosis-Wirkungs-Beziehung zu bestehen.

Typ-2-Diabetes und Depression folgen oft aufeinander

14.05.2024 Typ-2-Diabetes Nachrichten

Menschen mit Typ-2-Diabetes sind überdurchschnittlich gefährdet, in den nächsten Jahren auch noch eine Depression zu entwickeln – und umgekehrt. Besonders ausgeprägt ist die Wechselbeziehung laut GKV-Daten bei jüngeren Erwachsenen.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Spezielles Sportprogramm bei einer Reihe von psychischen Erkrankungen effektiv

08.05.2024 Psychotherapie Nachrichten

Sportliche Betätigung hilft nicht nur bei Depression, sondern auch in Gruppen von Patientinnen und Patienten mit unterschiedlichen psychischen Erkrankungen, wie Insomnie, Panikattacken, Agoraphobie und posttraumatischem Belastungssyndrom. Sie alle profitieren längerfristig.

Update Psychiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.